Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
GENEVA, SWITZERLAND / ACCESSWIRE / November 29, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent com...
NRx Pharmaceuticals (NASDAQ:NRXP) has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with Zyesami (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. Shares up 34....
Relief Therapeutics (OTCQB:RLFTF) has signed a collaboration agreement with InveniAI LLC, a U.S. based company that has pioneered the application of artificial intelligence (AI) and machine learning across biopharma and other industries, in order to identify promising drug candidates to treat...
Relief Therapeutics (OTCQB:RLFTF) announces that its collaboration partner, NRx Pharmaceuticals (NASDAQ:NRXP) has issued a CEO Update announcing that the FDA has denied Breakthrough Therapy Designation (BTD) for aviptadil (Zyesami). In denying BTD, the FDA noted that NRx did not distinguish t...
GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has signed a collaboration agreement (the " Collaboration ") with InveniAI LLC (" InveniAI "), a U.S. based company that has pioneer...
Geneva, Switzerland, November 24, 2021 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its collabo...
Relief Therapeutics (OTCQB:RLFTF) announces that its Form F-6 registration statement has become effective, and that the company has launched its Level 1 American Depositary Receipt (ADR) program in the U.S. It is expected that Relief's ADRs will begin trading on the OTC market today, November...
GENEVA, SWITZERLAND / ACCESSWIRE / November 18, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), announced today that its Form F-6 registration statement has become effective, and that Relief has launched its Level 1 American Depositary Receipt ("ADR") program in ...
GENEVA, SWITZERLAND / ACCESSWIRE / November 12, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its U....
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today provided a corporate update detailing, amo...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
Mondobiotech Holding AG Basel Website:
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, ann...
GENEVA, SWITZARLAND / ACCESSWIRE / May 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Mee...
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...